Financiere des Professionnels Fonds d investissement inc. Buys 1,294 Shares of Medpace Holdings, Inc. $MEDP

Financiere des Professionnels Fonds d investissement inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 176.8% during the third quarter, Holdings Channel reports. The firm owned 2,026 shares of the company’s stock after acquiring an additional 1,294 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Medpace were worth $1,042,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Employees Retirement System of Texas bought a new position in Medpace in the 2nd quarter valued at about $36,000. IFP Advisors Inc raised its position in shares of Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after buying an additional 134 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after acquiring an additional 203 shares during the period. Finally, Cary Street Partners Investment Advisory LLC boosted its position in shares of Medpace by 514.3% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after acquiring an additional 180 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $571.02 on Friday. The firm’s fifty day moving average price is $579.51 and its two-hundred day moving average price is $490.69. The stock has a market cap of $16.09 billion, a PE ratio of 39.93, a PEG ratio of 1.92 and a beta of 1.43. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the company earned $3.01 EPS. Medpace’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on MEDP shares. TD Cowen lifted their price objective on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Finally, Mizuho raised their price objective on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average target price of $490.82.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.